Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

We studied the diagnostic value of CSF Aβ42/tau versus low Aβ1–42% and high Aβ1–40(ox)% levels for differential diagnosis of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), respectively. CSF of 45 patients with AD, 15 with DLB, 21 with Parkinson's disease dementia (PDD), and 40 nondemented disease controls (NDC) was analyzed by Aβ-SDS-PAGE/immunoblot and ELISAs (Aβ42 and tau). Aβ42/tau lacked specificity in discriminating AD from DLB and PDD. Best discriminating biomarkers were Aβ1–42% and Aβ1–40(ox)% for AD and DLB, respectively. AD and DLB could be differentiated by both Aβ1–42% and Aβ1–40(ox)% with an accuracy of 80% at minimum. Thus, we consider Aβ1–42% and Aβ1–40(ox)% to be useful biomarkers for AD and DLB, respectively. We propose further studies on the integration of Aβ1–42% and Aβ1–40(ox)% into conventional assay formats. Moreover, future studies should investigate the combination of Aβ1–40(ox)% and CSF alpha-synuclein for the diagnosis of DLB.